应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
交易中 05-06 12:38:36 EDT
184.37
+3.13
+1.73%
最高
185.43
最低
183.55
成交量
77.38万
今开
184.57
昨收
181.24
日振幅
1.04%
总市值
2,860亿
流通市值
2,847亿
总股本
15.51亿
成交额
1.43亿
换手率
0.05%
流通股本
15.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
诚益生物冲刺港股：年亏损4460万美元 业务深度绑定阿斯利康
雷递网 · 05-03
诚益生物冲刺港股：年亏损4460万美元 业务深度绑定阿斯利康
伯恩斯坦将阿斯利康目标价从20500便士下调至18600便士。
智通财经 · 05-01
伯恩斯坦将阿斯利康目标价从20500便士下调至18600便士。
阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过
环球市场播报 · 05-01
阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过
FDA顾问委员会推荐阿斯利康Truqap用于PTEN缺陷型转移性激素敏感性前列腺癌
美股速递 · 05-01
FDA顾问委员会推荐阿斯利康Truqap用于PTEN缺陷型转移性激素敏感性前列腺癌
阿斯利康行使选择权 根据协议条款向Pintree Therapeutics支付2500万美元交割款项
美股速递 · 04-30
阿斯利康行使选择权 根据协议条款向Pintree Therapeutics支付2500万美元交割款项
阿斯利康宣布3亿英镑对英投资，涵盖去年暂停的剑桥研发基地后续建设
美股速递 · 04-29
阿斯利康宣布3亿英镑对英投资，涵盖去年暂停的剑桥研发基地后续建设
阿斯利康CEO：英美医药协议将惠及患者，提升药物可及性
美股速递 · 04-29
阿斯利康CEO：英美医药协议将惠及患者，提升药物可及性
阿斯利康(AZN.US)哮喘三联疗法获批上市
智通财经 · 04-29
阿斯利康(AZN.US)哮喘三联疗法获批上市
明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期
智通财经 · 04-29
明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期
阿斯利康(AZN.US)“双免疫治疗”新适应症在华获批上市
智通财经 · 04-27
阿斯利康(AZN.US)“双免疫治疗”新适应症在华获批上市
从“癌种攻坚”到“生态引领”： 阿斯利康肿瘤防治的中国答卷
21世纪经济报道 · 04-21
从“癌种攻坚”到“生态引领”： 阿斯利康肿瘤防治的中国答卷
大摩：将阿斯利康目标价上调至16500便士
中金财经 · 04-08
大摩：将阿斯利康目标价上调至16500便士
全球生物医药巨头阿斯利康落子广州；深圳即将启用广东首个机器人停车场丨大湾区财经早参
每日经济新闻 · 04-08
全球生物医药巨头阿斯利康落子广州；深圳即将启用广东首个机器人停车场丨大湾区财经早参
核药“热战”：阿斯利康为何押注广州？
21世纪经济报道 · 03-31
核药“热战”：阿斯利康为何押注广州？
阿斯利康(AZN)罕见病创新药在华获批
金吾财讯 · 03-30
阿斯利康(AZN)罕见病创新药在华获批
阿里健康与阿斯利康达成战略合作
新华财经 · 03-30
阿里健康与阿斯利康达成战略合作
科赛优®在华获批用于治疗伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病（NF1-PN）儿童及成人患者
美通社 · 03-30
科赛优®在华获批用于治疗伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病（NF1-PN）儿童及成人患者
加科思-B(01167)收到阿斯利康就泛KRAS抑制剂JAB-23E73订立的许可及合作协议项下的1亿美元首付款
智通财经 · 03-30
加科思-B(01167)收到阿斯利康就泛KRAS抑制剂JAB-23E73订立的许可及合作协议项下的1亿美元首付款
阿斯利康COPD试验取得积极成果，股价应声大涨
投资观察 · 03-27
阿斯利康COPD试验取得积极成果，股价应声大涨
阿斯利康涨3.5%，其肺病药物临床试验意外取得成功（竞品均已失败）
环球市场播报 · 03-27
阿斯利康涨3.5%，其肺病药物临床试验意外取得成功（竞品均已失败）
加载更多
公司概况
公司名称：
阿斯利康
所属市场：
NYSE
上市日期：
--
主营业务：
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。
发行价格：
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":184.37,"timestamp":1778085516585,"preClose":181.24,"halted":0,"volume":773843,"delay":0,"changeRate":0.0172699183403222,"floatShares":1544000000,"shares":1551000000,"eps":6.639935,"marketStatus":"交易中","change":3.13,"latestTime":"05-06 12:38:36 EDT","open":184.57,"high":185.43,"low":183.55,"amount":142808794.52756,"amplitude":0.010373,"askPrice":184.49,"askSize":10,"bidPrice":184.33,"bidSize":1,"shortable":3,"etf":0,"ttmEps":6.639935,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778097600000},"marketStatusCode":2,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":181.24,"dividendRate":0.017203,"preHourTrading":{"tag":"盘前","latestPrice":184.59,"preClose":181.24,"latestTime":"09:29 EDT","volume":19112,"amount":3530471.65368,"timestamp":1778074199999,"change":3.35,"changeRate":0.018484,"amplitude":0.008056},"postHourTrading":{"tag":"盘后","latestPrice":181.24,"preClose":181.24,"latestTime":"19:55 EDT","volume":2613,"amount":473462.1378,"timestamp":1778025301659,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.630444,"impliedVol":0.283,"impliedVolPercentile":0.5458},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2632260556","title":"诚益生物冲刺港股：年亏损4460万美元 业务深度绑定阿斯利康","url":"https://stock-news.laohu8.com/highlight/detail?id=2632260556","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632260556?lang=zh_cn&edition=full","pubTime":"2026-05-03 10:35","pubTimestamp":1777775725,"startTime":"0","endTime":"0","summary":"诚益生物开曼有限公司（简称：“诚益生物”）日前更新招股书，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260503/6391340131178578595887971.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260503/6391340131178578595887971.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33522/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["LU2237443465.HKD","VXUS","LU0889565916.HKD","AZN","LU1829250122.USD","LU2456880835.USD","LU2462157665.USD","LU2237443622.USD","LU2237443895.HKD","LU2236285917.USD","LU0320765992.SGD","BK4007","LU0058720904.USD","LU2237443549.SGD","LU2237443978.SGD","LU0109394709.USD","LU0289739699.SGD","BK4588","BK4585","LU2237443382.USD","BK4568","LU2417539215.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632619163","title":"伯恩斯坦将阿斯利康目标价从20500便士下调至18600便士。","url":"https://stock-news.laohu8.com/highlight/detail?id=2632619163","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632619163?lang=zh_cn&edition=full","pubTime":"2026-05-01 19:09","pubTimestamp":1777633776,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZN","AZN.UK","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632504618","title":"阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2632504618","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632504618?lang=zh_cn&edition=full","pubTime":"2026-05-01 16:14","pubTimestamp":1777623240,"startTime":"0","endTime":"0","summary":"在乳腺癌候选药物未能在一项关键的咨询委员会投票中获得支持后，英国制药集团阿斯利康表示，该公司将继续与美国监管机构合作，对该药物进行审查。该公司周四晚间表示，美国食品药品管理局的肿瘤药物咨询委员会以6比3的投票结果，对乳腺癌治疗候选药物camizestrant的获益-风险评估给出否定性意见。阿斯利康的股价在周五开盘交易中下跌了约1.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-01/doc-inhwktza5459710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0109394709.USD","LU2462157665.USD","LU2237443382.USD","LU2237443978.SGD","BK4007","LU2237443622.USD","LU0058720904.USD","LU2236285917.USD","BK4568","LU0289739699.SGD","LU2237443895.HKD","BK4585","LU2237443465.HKD","LU2456880835.USD","LU1829250122.USD","AZNH","AZN","LU0320765992.SGD","LU2417539215.USD","IE00B3T34201.USD","AZN.UK","LU0889565916.HKD","LU2237443549.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161357099","title":"FDA顾问委员会推荐阿斯利康Truqap用于PTEN缺陷型转移性激素敏感性前列腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1161357099","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161357099?lang=zh_cn&edition=full","pubTime":"2026-05-01 05:49","pubTimestamp":1777585759,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局顾问委员会近日对阿斯利康制药旗下抗癌药物Truqap给予积极推荐，支持其用于治疗PTEN缺陷型转移性激素敏感性前列腺癌患者。该研究证实，在PTEN缺失的转移性激素敏感性前列腺癌患者中，Truqap治疗方案能显著延长影像学无进展生存期，为这类特定人群提供了新的精准治疗选择。FDA通常遵循顾问委员会的建议，但最终决定仍待官方审评。若获批，Truqap将成为首个针对PTEN缺陷型mHSPC的靶向疗法，填补当前治疗格局中的重要空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0957799991.USD","LU1046234339.USD","LU0266013472.USD","LU1267930573.SGD","SG9999013999.USD","LU0889566641.SGD","LU1078025761.USD","LU0211326755.USD","LU0640478417.SGD","LU0889565080.SGD","LU2089284900.SGD","LU0496365809.HKD","LU0784385170.HKD","LU2324357040.USD","LU1923622614.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU0171293334.USD","LU2468319806.SGD","LU1481599808.USD","LU0784383803.USD","LU1496350502.SGD","LU0310800965.SGD","LU1267930490.SGD","LU2108987350.USD","LU0052756011.USD","LU0077335932.USD","LU0920783379.SGD","LU1267930813.SGD","LU0792757196.USD","LU0122379950.USD","LU0575583348.USD","LU1057294990.SGD","LU0553294199.USD","LU1301847155.USD","LU1983299246.USD","LU0859254822.USD","AZN.UK","LU0310800379.SGD","LU0972486137.USD","LU0969580561.USD","LU1273509221.SGD","LU0114720955.EUR","BK5011","LU1496350171.SGD","LU1487256676.USD","LU0920840948.USD","LU0708994859.HKD","LU1267930227.SGD","LU1170363599.USD","LU2293690249.USD","LU2091194634.USD","LU0432979614.USD","LU2112291526.USD","LU1153584641.USD","LU1481600234.SGD","LU0557290698.USD","LU2355687059.USD","AZNH","LU2089283258.USD","LU2125909593.SGD","LU1015430645.USD","LU0949170772.SGD","LU0211327993.USD","SG9999001176.USD","IE00B4R5TH58.HKD","LU0661504455.SGD","LU0887340254.USD","LU1104425308.USD","LU0345777147.USD","LU0784384876.USD","LU2357627491.SGD","LU2023251221.USD","LU1814569148.SGD","IE0009355771.USD","LU0310799852.SGD","LU0857590862.USD","LU1989772923.USD","LU2114397693.USD","LU0823399737.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU1064927863.SGD","LU0011850046.USD","LU1084165304.USD","LU1989771016.USD","LU2433249047.HKD","LU0997586515.USD","LU0345777659.USD","LU0757432116.USD","LU0976567544.SGD","LU1989772840.SGD","LU0823416689.USD","LU1880407132.USD","IE0034235188.USD","LU2279689827.SGD","LU1019632923.USD","LU1019634622.SGD","LU0029864427.USD","IE00BJT1NW94.SGD","IE00BKPKM643.USD","LU2125909247.SGD","LU0128525689.USD","LU0158827948.USD","LU0963555726.SGD","SGXZ57979304.SGD","LU0047473722.SGD","LU0211326839.USD","AZN","LU0960981461.USD","SG9999001176.SGD","LU1196032939.SGD","LU0784385840.USD","LU0997586432.USD","LU2539964713.USD","LU1003077747.HKD","IE0002141913.USD","LU0964806797.USD","LU1119994496.HKD","LU0738911758.USD","LU1023059063.AUD","LU1153585028.USD","LU0211328371.USD","LU1061106388.HKD","LU0545039389.USD","LU1051770623.HKD","LU0203345920.USD","LU0499090636.EUR","LU0203347892.USD","LU0390134368.USD","IE00B2B36J28.USD","LU0058720904.USD","LU0949170426.SGD","LU2089984988.USD","LU2293690082.USD","LU0289739699.SGD","LU0047473722.EUR","LU0128525929.USD","LU0827474353.SGD","IE00B3T34201.USD","LU1261432733.SGD","LU0526926950.USD","LU1880407215.USD","LU0882574055.USD","LU1003076772.USD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171095508","title":"阿斯利康行使选择权 根据协议条款向Pintree Therapeutics支付2500万美元交割款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1171095508","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171095508?lang=zh_cn&edition=full","pubTime":"2026-04-30 07:03","pubTimestamp":1777503805,"startTime":"0","endTime":"0","summary":"根据双方达成的协议条款，阿斯利康制药行使选择权，此举触发了其向Pintree Therapeutics支付一笔高达2500万美元的选择权交割款项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0499090636.EUR","LU1814569148.SGD","LU1019632923.USD","LU2324357040.USD","IE00BJT1NW94.SGD","LU1487256676.USD","LU1153584641.USD","LU0889565080.SGD","LU1119994496.HKD","LU2089284900.SGD","SGXZ57979304.SGD","LU0171293334.USD","LU0211328371.USD","LU0158827948.USD","LU0661504455.SGD","LU0047473722.EUR","LU0823399737.USD","LU0949170426.SGD","LU0526926950.USD","LU0310800379.SGD","LU1104425308.USD","LU0784384876.USD","LU0052756011.USD","LU0310799852.SGD","LU0640478417.SGD","LU0949170772.SGD","LU1983299246.USD","LU2023251221.USD","LU2468319806.SGD","LU1267930573.SGD","LU0289739699.SGD","LU1481599808.USD","LU1496350171.SGD","LU2125909247.SGD","IE0034235188.USD","LU0122379950.USD","LU0827474353.SGD","LU1153585028.USD","LU1023059063.AUD","IE0002141913.USD","LU1291159041.SGD","LU2355687059.USD","LU1301847155.USD","AZNH","LU0496365809.HKD","LU2293690082.USD","LU0553294199.USD","LU0211326839.USD","LU1196032939.SGD","LU0963555726.SGD","LU0997586515.USD","LU0969580561.USD","LU1046234339.USD","LU0575583348.USD","AZN.UK","LU0557290698.USD","LU1989771016.USD","LU2108987350.USD","LU1880407132.USD","LU2089283258.USD","LU0823416689.USD","LU1057294990.SGD","LU0784385170.HKD","LU1003077747.HKD","LU1989772840.SGD","LU2133065610.SGD","LU0310800965.SGD","LU0058720904.USD","LU0784385840.USD","LU0738911758.USD","IE00B3T34201.USD","BK5011","LU0997586432.USD","LU1481600234.SGD","LU0029864427.USD","LU1170363599.USD","LU1989772923.USD","LU2112291526.USD","LU1003076772.USD","LU0266013472.USD","LU0128525929.USD","LU0957799991.USD","LU0889566641.SGD","SG9999013999.USD","LU0390134368.USD","AZN","LU0857590862.USD","LU2279689827.SGD","LU1273509221.SGD","LU0114720955.EUR","LU2125909593.SGD","LU0128525689.USD","LU0976567544.SGD","LU2089984988.USD","SG9999001176.SGD","SG9999001176.USD","LU0859254822.USD","LU1051770623.HKD","LU1267930227.SGD","LU1267930490.SGD","LU1061106388.HKD","LU1015430645.USD","IE00B4R5TH58.HKD","LU0920840948.USD","LU1064927863.SGD","LU1084165304.USD","LU0784383803.USD","LU0964806797.USD","IE00B2B36J28.USD","LU2293690249.USD","LU1880407215.USD","LU1323610961.USD","LU2433249047.HKD","IE00BJJMRZ35.SGD","LU0545039389.USD","IE00BKPKM643.USD","LU0960981461.USD","LU0345777147.USD","LU0882574055.USD","LU2539964713.USD","LU0211326755.USD","LU1261432733.SGD","LU0757432116.USD","LU0203345920.USD","LU0345777659.USD","LU0047473722.SGD","LU0887340254.USD","LU0792757196.USD","IE00BFTCPJ56.SGD","LU1923622614.USD","LU1496350502.SGD","LU0920783379.SGD","LU0077335932.USD","IE0009355771.USD","LU0011850046.USD","LU0972486137.USD","LU1267930813.SGD","LU2091194634.USD","LU0708994859.HKD","LU1019634622.SGD","LU0203347892.USD","LU0432979614.USD","LU1078025761.USD","LU2114397693.USD","LU0211327993.USD","LU2357627491.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159873248","title":"阿斯利康宣布3亿英镑对英投资，涵盖去年暂停的剑桥研发基地后续建设","url":"https://stock-news.laohu8.com/highlight/detail?id=1159873248","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159873248?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:51","pubTimestamp":1777463500,"startTime":"0","endTime":"0","summary":"阿斯利康制药首席执行官帕斯卡尔·索里奥特今日宣布，公司将对英国投资3亿英镑。此项投资计划包含完成去年一度暂停的剑桥研发基地建设项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800965.SGD","IE00BJT1NW94.SGD","LU2539964713.USD","LU0114720955.EUR","LU1267930490.SGD","LU1023059063.AUD","LU0792757196.USD","LU1267930813.SGD","LU0390134368.USD","LU0920783379.SGD","LU1989772840.SGD","LU0203345920.USD","LU0496365809.HKD","LU1273509221.SGD","IE0009355771.USD","LU0784384876.USD","LU0827474353.SGD","LU0575583348.USD","AZNH","LU0557290698.USD","LU0963555726.SGD","LU0964806797.USD","LU1153585028.USD","LU1989772923.USD","LU0957799991.USD","LU0077335932.USD","LU0128525929.USD","LU0203347892.USD","LU2125909247.SGD","IE00BKPKM643.USD","LU1261432733.SGD","LU0211328371.USD","LU0784383803.USD","LU0823399737.USD","LU0997586432.USD","LU1267930573.SGD","LU0211327993.USD","IE00B3T34201.USD","IE00BFTCPJ56.SGD","LU0499090636.EUR","LU1061106388.HKD","LU1880407215.USD","LU0640478417.SGD","LU1003076772.USD","LU1983299246.USD","LU0972486137.USD","LU2433249047.HKD","LU1487256676.USD","LU2468319806.SGD","LU0661504455.SGD","LU0432979614.USD","LU1104425308.USD","LU0047473722.EUR","LU0052756011.USD","LU1267930227.SGD","IE0034235188.USD","LU0882574055.USD","LU0859254822.USD","LU1019632923.USD","IE0002141913.USD","LU0058720904.USD","LU0784385170.HKD","LU1084165304.USD","LU2324357040.USD","LU1051770623.HKD","LU0289739699.SGD","AZN.UK","LU1814569148.SGD","LU0211326755.USD","LU1170363599.USD","LU1078025761.USD","LU0708994859.HKD","LU0545039389.USD","LU1046234339.USD","LU1119994496.HKD","LU1301847155.USD","AZN","LU0857590862.USD","LU2133065610.SGD","LU1019634622.SGD","LU0158827948.USD","LU0011850046.USD","LU2089984988.USD","LU0997586515.USD","LU2091194634.USD","LU1481600234.SGD","LU1989771016.USD","LU1003077747.HKD","SG9999001176.SGD","BK5011","LU0526926950.USD","LU0784385840.USD","LU2089283258.USD","LU1057294990.SGD","LU1153584641.USD","LU0738911758.USD","LU2293690082.USD","LU2357627491.SGD","LU0949170772.SGD","LU0889565080.SGD","IE00B2B36J28.USD","LU0920840948.USD","LU0949170426.SGD","LU0960981461.USD","IE00BJJMRZ35.SGD","LU0171293334.USD","LU1064927863.SGD","LU0887340254.USD","LU2355687059.USD","LU1496350171.SGD","LU2125909593.SGD","LU0976567544.SGD","LU1291159041.SGD","IE00B4R5TH58.HKD","LU0029864427.USD","LU0345777659.USD","LU1880407132.USD","LU0047473722.SGD","LU1923622614.USD","LU1323610961.USD","LU2279689827.SGD","LU0757432116.USD","SG9999001176.USD","LU0553294199.USD","LU2108987350.USD","LU1196032939.SGD","LU1496350502.SGD","LU0969580561.USD","SGXZ57979304.SGD","LU0823416689.USD","LU0122379950.USD","LU0266013472.USD","LU0889566641.SGD","LU1481599808.USD","LU0211326839.USD","LU2023251221.USD","SG9999013999.USD","LU1015430645.USD","LU2114397693.USD","LU2089284900.SGD","LU0128525689.USD","LU0345777147.USD","LU2293690249.USD","LU0310799852.SGD","LU2112291526.USD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125435733","title":"阿斯利康CEO：英美医药协议将惠及患者，提升药物可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1125435733","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125435733?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:35","pubTimestamp":1777462524,"startTime":"0","endTime":"0","summary":"阿斯利康制药首席执行官帕斯卡尔·索里奥表示，近期达成的美国与英国之间的医药合作协议，将有效改善患者的药物获取渠道。索里奥在媒体电话会议上指出，这一合作框架有望简化新药审批流程，并促进创新疗法更快速地惠及有需要的患者群体。他强调，加强国际协作对于应对全球健康挑战至关重要，而此项协议正是推动医药领域进步的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930813.SGD","LU2125909593.SGD","LU0203345920.USD","LU0211326755.USD","LU0557290698.USD","LU0266013472.USD","LU0345777659.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU0047473722.SGD","LU1267930573.SGD","IE0009355771.USD","LU1119994496.HKD","BK5011","LU1170363599.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU0882574055.USD","LU2112291526.USD","LU1003077747.HKD","LU1481600234.SGD","LU1064927863.SGD","LU1267930227.SGD","LU2108987350.USD","LU1061106388.HKD","SG9999001176.SGD","LU2433249047.HKD","LU0171293334.USD","LU0345777147.USD","LU2355687059.USD","LU0011850046.USD","LU0661504455.SGD","LU0920783379.SGD","LU1019632923.USD","LU0128525929.USD","LU1923622614.USD","LU2293690249.USD","LU0640478417.SGD","LU0784384876.USD","LU2468319806.SGD","LU1989772923.USD","AZN.UK","LU0052756011.USD","LU2357627491.SGD","LU1084165304.USD","LU2114397693.USD","IE00B3T34201.USD","SG9999013999.USD","LU1481599808.USD","LU0960981461.USD","LU1104425308.USD","LU1051770623.HKD","LU1880407132.USD","LU1989771016.USD","LU0823399737.USD","LU2089284900.SGD","LU0920840948.USD","LU1989772840.SGD","LU0122379950.USD","LU0128525689.USD","LU1015430645.USD","LU1003076772.USD","LU0211326839.USD","LU2324357040.USD","LU0310800379.SGD","LU1019634622.SGD","IE0034235188.USD","SG9999001176.USD","LU0738911758.USD","LU0708994859.HKD","LU0432979614.USD","LU2133065610.SGD","LU0545039389.USD","LU1983299246.USD","LU0963555726.SGD","LU1291159041.SGD","LU0289739699.SGD","LU1301847155.USD","LU1273509221.SGD","IE00BKPKM643.USD","LU0964806797.USD","LU0827474353.SGD","LU2089283258.USD","SGXZ57979304.SGD","AZNH","LU1267930490.SGD","LU0859254822.USD","LU1496350171.SGD","LU0949170772.SGD","LU2279689827.SGD","LU0889566641.SGD","LU1880407215.USD","LU0889565080.SGD","LU2089984988.USD","LU1496350502.SGD","LU1814569148.SGD","LU1487256676.USD","LU2293690082.USD","LU0784385840.USD","LU0077335932.USD","LU0972486137.USD","LU1261432733.SGD","LU0553294199.USD","LU0029864427.USD","AZN","LU0887340254.USD","LU1078025761.USD","LU2125909247.SGD","LU0158827948.USD","LU2023251221.USD","LU0211328371.USD","LU0575583348.USD","LU0496365809.HKD","LU0957799991.USD","LU0969580561.USD","LU1153584641.USD","LU0784385170.HKD","LU2539964713.USD","LU0390134368.USD","LU0310799852.SGD","LU0526926950.USD","LU0997586432.USD","LU0857590862.USD","IE00B4R5TH58.HKD","LU0058720904.USD","LU1046234339.USD","LU1323610961.USD","LU0792757196.USD","LU0976567544.SGD","LU0211327993.USD","IE00BJT1NW94.SGD","LU0047473722.EUR","LU0949170426.SGD","LU0114720955.EUR","LU1196032939.SGD","LU1153585028.USD","LU0823416689.USD","LU2091194634.USD","LU0499090636.EUR","LU0310800965.SGD","LU0784383803.USD","LU0757432116.USD","IE00BJJMRZ35.SGD","LU0997586515.USD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631567485","title":"阿斯利康(AZN.US)哮喘三联疗法获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2631567485","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631567485?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:28","pubTimestamp":1777451308,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月28日，阿斯利康宣布布地格福吸入气雾剂获得FDA批准用于维持治疗12岁及以上哮喘患者。布地格福是阿斯利康开发的一款固定剂量三联疗法，包含布地奈德、格隆溴铵、福莫特罗三种药物活性成分。FDA此次批准是基于两项III期研究的积极结果。结果显示，相较于Symbicort组，布地格福吸入气雾剂组患者的1秒内用力呼气量显著改善，并且重度哮喘恶化发生率显著降低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","LU1829250122.USD","IE00B3T34201.USD","LU0109394709.USD","LU2237443549.SGD","LU0889565916.HKD","LU2237443622.USD","LU2237443382.USD","AZN","LU2462157665.USD","LU2237443978.SGD","BK4588","BK4007","LU2237443465.HKD","LU0320765992.SGD","LU2417539215.USD","LU0289739699.SGD","LU2237443895.HKD","LU2456880835.USD","IPOS","LU2236285917.USD","BK4568","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631561829","title":"明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2631561829","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631561829?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:10","pubTimestamp":1777446600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，受明星抗癌药物需求的推动，阿斯利康第一季度利润增长超预期。财报显示，阿斯利康第一季度总营收152.88亿美元，同比增长8%，超出市场预期；调整后每股收益为 2.58 美元，高于分析师预期的 2.55 美元。继 2025 年股价大幅上涨 32% 后，阿斯利康的股价今年至今基本持平。虽然抗癌药物一直是阿斯利康成功的关键，但其针对心血管和代谢疾病的产品组合销售额在第一季度有所下降。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436063.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"明星抗癌药需求强劲，阿斯利康Q1营收和利润均超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630369561","title":"阿斯利康(AZN.US)“双免疫治疗”新适应症在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2630369561","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630369561?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:54","pubTimestamp":1777280053,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日，阿斯利康宣布，中国国家药品监督管理局已正式批准英飞凡联合英卓凡用于晚期或不可切除的肝细胞癌成人患者的一线治疗。本次新适应症的批准是基于全球 III 期 HIMALAYA 研究及中国队列的积极结果。数据显示，STRIDE 方案组与度伐利尤单抗单药组的三级及以上治疗相关不良事件发生率分别为 24.1% 和 12.4%，均低于索拉非尼组的 40.2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","IPOS","LU2462157665.USD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","BK4588","LU2237443549.SGD","LU2456880835.USD","LU2236285917.USD","BK4585","BK4568","LU2237443465.HKD","LU0058720904.USD","AZN","LU2237443622.USD","LU0289739699.SGD","LU2237443382.USD","IE00B3T34201.USD","LU2237443895.HKD","LU2237443978.SGD","LU2417539215.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892730","title":"从“癌种攻坚”到“生态引领”： 阿斯利康肿瘤防治的中国答卷","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892730","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629892730?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:33","pubTimestamp":1776760380,"startTime":"0","endTime":"0","summary":"癌症长期位居全球第二大致死原因，而中国以全球最高的新发和死亡人数，站在抗癌最前线。行业正直面一个关键问题：如何通过真正的科学突破，持续降低死亡负担，改善患者生存期与生活质量。这从来不是一句空泛的口号，而是一场必须打赢的硬仗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604213712331011.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604213712331011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU2237443465.HKD","LU2237443549.SGD","BK4588","LU2237443622.USD","LU2237443382.USD","LU0109394709.USD","LU2236285917.USD","LU0289739699.SGD","LU2456880835.USD","LU0889565916.HKD","LU2417539215.USD","LU2462157665.USD","BK4568","IE00B3T34201.USD","LU1829250122.USD","LU2237443978.SGD","BK4007","LU0058720904.USD","LU2237443895.HKD","AZN","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625990082","title":"大摩：将阿斯利康目标价上调至16500便士","url":"https://stock-news.laohu8.com/highlight/detail?id=2625990082","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625990082?lang=zh_cn&edition=full","pubTime":"2026-04-08 14:27","pubTimestamp":1775629621,"startTime":"0","endTime":"0","summary":"摩根士丹利将阿斯利康目标股价从16000便士上调至16500便士。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260408/32130641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625027964","title":"全球生物医药巨头阿斯利康落子广州；深圳即将启用广东首个机器人停车场丨大湾区财经早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2625027964","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625027964?lang=zh_cn&edition=full","pubTime":"2026-04-08 07:05","pubTimestamp":1775603119,"startTime":"0","endTime":"0","summary":"｜2026年4月8日星期三｜NO.1清明假期广东旅游收入超百亿元“广东发布”微信公众号4月7日消息，据初步测算，2026年清明假期三天（4月4日至6日），广东接待游客1985.1万人次，实现旅游收入104.3亿元。点评：百亿文旅收入印证广东内需韧性、消费活力、湾区磁吸效应，为一季度经济收官、二季度内需扩容打下坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604083696940526.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083696940526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2236285917.USD","LU2462157665.USD","LU2417539215.USD","AZN","LU2237443895.HKD","159983","LU2237443465.HKD","BK4585","161726","LU0289739699.SGD","LU2456880835.USD","BK4568","ROBO","399441","XBI","BK4588","BK4007","LU0320765992.SGD","LU2237443978.SGD","LU2237443622.USD","LU0058720904.USD","BK4581","LU0889565916.HKD","LU2237443382.USD","LU1829250122.USD","LU2237443549.SGD","IE00B3T34201.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623856985","title":"核药“热战”：阿斯利康为何押注广州？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623856985","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623856985?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:47","pubTimestamp":1774954020,"startTime":"0","endTime":"0","summary":"继ADC（抗体偶联药物）之后，核药正在成为全球生物医药市场最炙手可热的赛道。诺华的Pluvicto（针对前列腺癌细胞的核药）2025年全年销售额达19.94亿美元，连续两年全球销售额同比增长42%，是全球首个突破10亿美元的核药。这验证了核药的商业潜力，短短两年，跨国药企在核药领域砸下数百亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690600660.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690600660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","BK4588","LU2237443549.SGD","LU0058720904.USD","BK4007","LU0889565916.HKD","LU0289739699.SGD","LU2417539215.USD","LU0320765992.SGD","BK4585","LU2462157665.USD","LU2237443465.HKD","AZN","LU0109394709.USD","LU2456880835.USD","BK4568","LU2237443978.SGD","LU2237443382.USD","IE00B3T34201.USD","LU2237443622.USD","LU2237443895.HKD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623154273","title":"阿斯利康(AZN)罕见病创新药在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2623154273","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623154273?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:55","pubTimestamp":1774864518,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)宣布，中国国家药品监督管理局已正式批准硫酸氢司美替尼胶囊（商品名：科赛优），用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤（PN）的1型神经纤维瘤病（NF1）儿童及成人患者的治疗。这是目前国内首个且唯一获批用于3岁及3岁以上该患者人群的治疗药物。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298501","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0109394709.USD","LU0289739699.SGD","06978","LU2417539215.USD","AZN","LU2456880835.USD","LU0058720904.USD","LU0889565916.HKD","LU0320765992.SGD","BK4588","LU1829250122.USD","LU2462157665.USD","159992","BK1161","BK1574","IE00B3T34201.USD","LU2236285917.USD","BK4585","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623124397","title":"阿里健康与阿斯利康达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2623124397","media":"新华财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623124397?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:27","pubTimestamp":1774859228,"startTime":"0","endTime":"0","summary":"新华财经北京3月30日电（记者沈寅飞）记者从阿里健康获悉，近日，阿斯利康全球商业副总裁SandraDisse，阿斯利康中国助理副总裁、生物制药业务早期管线负责人吴中一及阿斯利康中国零售团队到访杭州，走进阿里健康，围绕数智化健康生态与医学赋能下的服务模式展开深度交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688715385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0058720904.USD","LU0889565916.HKD","BK1247","BK1615","BK4585","BK1617","LU0109394709.USD","BK1591","BK1610","LU0320765992.SGD","LU2462157665.USD","BK4588","LU2417539215.USD","LU2456880835.USD","LU2236285917.USD","BK4007","LU0289739699.SGD","BK1142","BK1589","BK1501","IE00B3T34201.USD","00241","LU1829250122.USD","BK1584","BK1189","AZN","BK1502","BK1515","BK1571","BK4568"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623539793","title":"科赛优®在华获批用于治疗伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病（NF1-PN）儿童及成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2623539793","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623539793?lang=zh_cn&edition=full","pubTime":"2026-03-30 15:46","pubTimestamp":1774856760,"startTime":"0","endTime":"0","summary":"成为国内首个且唯一*获批用于3岁及3岁以上该患者人群的治疗药物 上海2026年3月30日 /美通社/ -- 阿斯利康宣布，中国国家药品监督管理局已正式批准科赛优，一种选择性、口服MEK抑制剂，用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病儿童及成人患者的治疗[1]。司美替尼已在美国、欧盟、日本、中国及其他国家/地区获批，用于治疗特定伴有症状且无法手术切除PN的 NF1 儿童患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4922084_ZH22084_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B3T34201.USD","LU2236285917.USD","LU2462157665.USD","LU0058720904.USD","LU0320765992.SGD","BK4585","LU2456880835.USD","LU2417539215.USD","LU1829250122.USD","BK4588","PN","ORR","AZN","LU0109394709.USD","LU0889565916.HKD","BK4096","BK4007","BK4568","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623369335","title":"加科思-B(01167)收到阿斯利康就泛KRAS抑制剂JAB-23E73订立的许可及合作协议项下的1亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2623369335","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623369335?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:02","pubTimestamp":1774828968,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，内容有关北京加科思新药研发有限公司(北京加科思，本集团的非全资附属公司)与AstraZeneca AB(阿斯利康)订立了许可与合作协议。本公司的附属公司北京加科思就其订立的许可及合作协议，已收到阿斯利康支付的1亿美元的首付款。该首付款的到账，进一步充盈了本集团的现金储备，也将为本集团后续创新肿瘤疗法管线研发的推进提供助力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","01167","BK4588","LU0109394709.USD","LU2236285917.USD","LU0289739699.SGD","LU2456880835.USD","BK1574","LU0889565916.HKD","LU2417539215.USD","BK1161","LU2462157665.USD","BK4568","IE00B3T34201.USD","LU1829250122.USD","BK4007","LU0058720904.USD","AZN","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197644035","title":"阿斯利康COPD试验取得积极成果，股价应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1197644035","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197644035?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:38","pubTimestamp":1774625932,"startTime":"0","endTime":"0","summary":"阿斯利康股价周五上涨约3.5%，此前该公司宣布其用于治疗慢性阻塞性肺病（COPD）的药物在两项大型试验中成功延缓了患者的症状恶化。COPD是一种致命的肺部疾病，通常由吸烟引起。\n该药物名为torzorakimab，其作用机制是通过减轻炎症和改善黏液功能失调来发挥作用——这两者正是COPD病情发展的关键驱动因素。慢性阻塞性肺病常被认为是全球第三大死亡原因。\n在这两项试验中，无论是当前吸烟者还是既往吸烟者，接受该药物治疗的患者发生中度至重度COPD急性加重的比率，均低于未使用该药物的对照组。\n尽管周五股价有所上涨，但阿斯利康的股价在整个三月份仍累计下跌约8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2456880835.USD","AZN","LU0889565916.HKD","LU2417539215.USD","LU2462157665.USD","BK4007","BK4585","BK4588","LU0320765992.SGD","LU1829250122.USD","LU0109394709.USD","LU0289739699.SGD","IE00B3T34201.USD","LU2236285917.USD","BK4568","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878036","title":"阿斯利康涨3.5%，其肺病药物临床试验意外取得成功（竞品均已失败）","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878036","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622878036?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:47","pubTimestamp":1774622820,"startTime":"0","endTime":"0","summary":"阿斯利康称，呼吸类药物 托佐利单抗 与安慰剂相比，在既往吸烟人群及总体患者中均减少了慢性阻塞性肺疾病的急性加重发作。 阿斯利康表示，完整试验数据将在即将召开的医学会议上公布。 阿斯利康在纽约上市的股票早盘逆势上涨3.5%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-27/doc-inhsmxrn5148304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","IE00B3T34201.USD","LU2456880835.USD","LU1829250122.USD","BK4007","LU0289739699.SGD","LU0889565916.HKD","AZN","LU0058720904.USD","LU2236285917.USD","LU2462157665.USD","LU2417539215.USD","BK4588","LU0320765992.SGD","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0291},{"period":"1month","weight":-0.1093},{"period":"3month","weight":-0.0331},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.257},{"period":"ytd","weight":-0.0142}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.007495},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018334},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}